Related Experiment Video
Updated: Jul 9, 2026

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
Therapeutic use of release-modifying drugs
1Alpha2 Pharmaceutica AB, 8 H. Rosenblum Street, Apt. 4650, Tel-Aviv 69379, Israel. langer.salomon@gmail.com
Abstract:
Presynaptic inhibitory or facilitatory autoreceptors are targets for the endogenous neurotransmitter of the respective neuron, and also for exogenous agonists, partial agonists and antagonists which can produce pharmacological actions through changes in transmitter release. In addition, presynaptic inhibitory or facilitatory heteroreceptors can also be acted upon by exogenous agonists, partial agonists or antagonists to induce changes in transmitter release with useful therapeutic effects. This article summarizes drugs that are known or likely to produce their therapeutic effects through presynaptic modulation of neurotransmitter release. Included are drugs acting on alpha and beta adrenoceptors, dopamine receptors, angiotensin, opioid, cannabinoid, and nicotinic acetylcholine receptors. Also discussed are changes in presynaptic receptor mechanisms produced by drugs that inhibit transmitter re-uptake.
Related Concept Videos
Modified-Release Drug Delivery Systems: Classification
Modified-Release Drug Delivery Systems: Overview
Modified-Release Drug Delivery Systems: Stimuli-Activated
Modified-Release Drug Delivery Systems: Influencing Factors
Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drugs Affecting Neurotransmitter Release or Uptake
